10 results about "Osmotic pump" patented technology

An electro-osmotic pump according to an embodiment of the present disclosure includes: a membrane that allows fluid movement; and a first electrode and a second electrode respectively provided on both sides of the membrane. The first electrode and the second electrode are formed of an impermeable substrate material and an electrode material coated thereon and have at least one fluid pathway. The impermeable substrate material is a plate-shaped substrate including at least one of a conducting material, a semiconducing material and a non-conducting material.

The invention provides a nicotine osmotic pump tablet and a preparation method thereof, the nicotine osmotic pump tablet is suitable for the oral cavity, the nicotine osmotic pump tablet comprises a tablet core, the tablet core comprises a drug-containing layer and a boosting layer, the drug-containing layer contains nicotine, and the ratio of the viscosity of the drug-containing layer to the viscosity of the boosting layer is 1: 1.5-1: 2; the tablet core is coated with the semi-permeable membrane; and the release hole can release nicotine after the semipermeable membrane permeates into the liquid. By adopting the nicotine osmotic pump tablet, nicotine is released at an approximately constant rate, the problems that oral mucosa and even stomach are stimulated to cause nausea and the like due to too fast release of nicotine are avoided, and meanwhile, sticky feeling or foreign body sensation is avoided during oral administration.

The application provides a tivozanib hydrochloride osmotic pump controlled-release tablet, which is characterized in that the tablet comprises a tablet core, and the tablet core comprises 100 parts of tivozanib hydrochloride, 30-60 parts of a retarder, 40-80 parts of a disintegrant and / or an osmotic pressure promoter, 40-90 parts of a cosolvent and 8-15 parts of a pore-forming agent in terms of weight fraction. The tivozanib hydrochloride osmotic pump controlled-release tablet can realize zero-order release and has a 24-hour cumulative release degree of more than 96%, so that the bioavailability of tivozanib in vivo is improved, and the frequency or dosage of oral solid preparations of tivozanib is reduced.

The invention relates to a detachable multi-organ chip co-culture device, and relates to the technical field of biological tissue engineering. Comprising an upper-layer fluid channel layer chip, a lower-layer micro-pit cell culture layer chip and an osmotic pump, the upper-layer fluid channel layer chip and the lower-layer micro-pit cell culture layer chip are respectively divided into five independent functional units, and the structures of the independent functional units are mutually independent; each independent functional unit of the upper fluid channel layer chip comprises a fluid channel structure; each independent functional unit of the lower-layer micro-pit cell culture layer chip comprises a micro-pit array structure and a micro-cavity, and the micro-pit array structure is arranged at the bottom of the micro-cavity; the upper-layer fluid channel layer chip and the lower-layer micro-pit cell culture layer chip are detachably combined and connected through a tenon-and-mortise structure; the osmotic pump is connected to the outlet end of the culture device and is used for constructing a dynamic perfusion culture environment. According to the invention, high-throughput culture of multiple organs can be realized, and the cell viability and proliferation state are good under a dynamic perfusion condition.

The present application provides a kind of felodipine osmotic pump controlled-release tablets and preparation method thereof, the osmotic pump controlled-release tablet is composed of osmotic pump controlled-release tablet core and water-insoluble coating layer (single side laser punching), the weight percentage of the felodipine osmotic pump controlled-release tablet contains immediate-release coating layer, controlled-release coating layer, propelling coating layer, water-insoluble coating layer is (5~20) :(5~30) :(10~50) :(5~30).The present application also provides a kind of preparation method of felodipine osmotic pump controlled-release tablet and its application in treating hypertension.The formulation of the felodipine osmotic pump controlled-release tablet of the present application is reasonable, and production process is simple and easy to control;By replacing traditional controlled-release tablet polyethylene oxide with different povidone, the controllability of felodipine osmotic pump controlled-release tablet preparation is significantly improved, and the difficulty of cleaning in production is reduced.

The invention discloses a citric acid tofacitinib osmotic pump sustained-release tablet, which comprises a citric acid tofacitinib tablet core and a sustained-release coating layer coated on the surface of the citric acid tofacitinib tablet core, the citric acid tofacitinib tablet core contains a waxy framework material, and the sustained-release coating layer contains a sustained-release membrane material and a pore-foaming agent; the slow-release membrane material is composed of eudragit RL and eudragit RS; the pore-foaming agent is a water-soluble pore-foaming agent. The invention also discloses a preparation method of the tofacitinib citrate osmotic pump sustained release tablet, which comprises the following steps: uniformly mixing the components of the tablet core, and tabletting to obtain the tablet core; coating the tablet core, preserving heat and curing to obtain the tofacitinib citrate osmotic pump sustained release tablet. According to the invention, the corrosion controlled release of the waxy framework material and the controlled release coating layer are hierarchically coupled, so that the drug release stability is obviously improved, the tolerance to the change of the gastrointestinal tract physiological environment is stronger, and the dissolution of the drug is not reduced after long-term storage.

The invention discloses an oral abutment with a drug sustained release function, and relates to the technical field of medical implantation. In order to solve the problem of poor treatment effect caused by insufficient drug concentration in the prior art, the invention designs the oral cavity abutment with the drug sustained-release function, and the oral cavity abutment is mainly structurally characterized by having three drug release modes which are mutually matched and linked; comprising a continuous release mode structure, an inflammation release mode structure and a stress release mode structure, in a daily state, a proper amount of medicine is continuously released through an osmotic pump, and the basic treatment concentration is maintained; after the mucosa around the implant is inflamed, the temperature rise of the inflammation part is detected, and the medicine release amount is increased through an inflammation release mode structure so as to strengthen the treatment effect; when a patient presses and occludes, the drug release amount is further supplemented through the stress release mode structure. According to the invention, the treatment effect on the mucositis around the implant is obviously improved, and the repair and regeneration of tissues around the implant are promoted.

Disclosed in the present invention are a topiroxostat osmotic pump tablet and a preparation method therefor. The topiroxostat osmotic pump tablet comprises: a tablet core consisting of a drug layer and a push layer; a semipermeable membrane coating outside the tablet core; a single drug-release orifice on the controlled-release tablet surface on the side of the drug layer; and an isolation film coating. Compared with topiroxostat tablets currently on the market, the topiroxostat osmotic pump controlled-release tablet prepared in the present invention achieves sustained and stable constant-rate drug release. The drug in a drug-release layer is not released immediately after a patient takes the drug; within the ten or more hours thereafter, the tablet can release the drug rhythmically under the action of the push layer, maintaining a steady-state plasma concentration, delaying the time at which the peak is reached, and prolonging the half-life of the drug, thereby improving bioavailability and achieving a sustained release effect of 12 h or more. Because a dual-layer osmotic pump controlled-release technology is used, the drug has stronger controllability, a more complete release, and higher bioavailability in comparison with single-layer tablets.

1. Name of the product in this design: Tablet punching machine. 2. Application of this design: This pharmaceutical equipment is mainly suitable for the permeation of the semi-permeable membrane on the upper part of the osmotic pump tablet. It is also suitable for punching, coding, and marking solid tablets or other solid preparations in the food or pharmaceutical industry. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D rendering 1.

The invention relates to the field of pharmaceutical preparations, in particular to a sacubitril and valsartan sodium controlled-release composition, a preparation method and application thereof, and a medicine. The invention provides a double-layer osmotic pump controlled release tablet of sacubitril and valsartan sodium, the tablet can continuously release medicine within 24 hours, and the oral administration of the original developed preparation on the market is changed into the oral administration of the original developed preparation once every two days, so that the medication compliance of a patient is greatly improved. Besides, the drug release of the preparation is characterized by zero-order release, the influence of the pH value of the environment is small, the influence of the complex environment of the gastrointestinal tract in the gastrointestinal tract is small, the safety of the drug is greatly improved, the fluctuation of the blood concentration caused by the peak valley effect of a common quick-release tablet is avoided, the steady-state blood concentration can be achieved after the preparation is taken once, and the preparation is safe and reliable. The effectiveness of the medicine is improved.